- Pharmacokinetics influenced by renal function, weight, albumin, and age.
- Day 22 concentration more than 32 μg/mL linked to higher success.
- Overall clinical success rate was 77%.
- No increase in serious adverse events with higher exposure.
- Supports potential for exposure-guided or additional dosing.
Source: JAMA Network Open
